(3aα,4β,7β,7aα)-4-(1,3,3a,4,7,7a-Hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile | 573760-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3aα,4β,7β,7aα)-4-(1,3,3a,4,7,7a-Hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile
• 英文别名: (3aα,4β,7β,7aα)-4-(1,3,3a,4,7,7a-Hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile；4-[(3aS,4R,7S,7aR)-4,7-dimethyl-1,3-dioxo-3a,7a-dihydro-4,7-epoxyisoindol-2-yl]-2-iodobenzonitrile
• CAS: 573760-07-3
• 化学式: C₁₇H₁₃IN₂O₃
• 分子量: 420.206
• InChiKey: MYMCJRUCQFIDPJ-AZQPONJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  70.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3aα,4β,7β,7aα)-4-(1,3,3a,4,7,7a-Hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile 在 disodium hydrogenphosphate 、 potassium dihydrogenphosphate 、 双氧水 作用下， 以25%的产率得到[3aR-(3aα,4β,5β,7β,7aα)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile
  参考文献：
  名称：

  Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists

  摘要：

  A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3 alpha S-(3 alpha alpha,4 beta, 5 beta, 7 beta, 7 alpha alpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.02.006
• 作为产物：
  描述：

  2,5-二甲基呋喃 、 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-iodobenzonitrile 以94%的产率得到(3aα,4β,7β,7aα)-4-(1,3,3a,4,7,7a-Hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile
  参考文献：
  名称：

  Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists

  摘要：

  A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3 alpha S-(3 alpha alpha,4 beta, 5 beta, 7 beta, 7 alpha alpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.02.006

文献信息

• Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：——

  公开号：US20040077605A1

  公开（公告）日：2004-04-22

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。
• METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
  申请人：Salvati E. Mark

  公开号：US20050119228A1

  公开（公告）日：2005-06-02

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。
• Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：Salvati E. Mark

  公开号：US20050272799A1

  公开（公告）日：2005-12-08

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环状化合物，使用这些化合物治疗与核激素受体相关的疾病，如癌症和免疫疾病的方法，以及含有这些化合物的制药组合物。
• US6953679B2
  申请人：——

  公开号：US6953679B2

  公开（公告）日：2005-10-11
• US7141578B2
  申请人：——

  公开号：US7141578B2

  公开（公告）日：2006-11-28